January 19, 2021 -- Contract development and manufacturing organization Intravacc reported that it has completed the process development and manufacturing of a polyvalent inactivated coxsackievirus B (CVB) vaccine for its client Provention Bio in less than 36 months.
A phase I clinical trial (protocol for coxsackievirus vaccine in healthy volunteers) evaluating the vaccine candidate has recently started.
The CVB vaccine candidate, PRV-101, was developed for the prevention of acute CVB infection and the potential delay or prevention of type 1 diabetes and celiac disease. Intravacc used its proprietary Vero cell platform to develop current good manufacturing practice (cGMP)-grade viral vaccine production processes for the polyvalent CVB vaccine candidate.
Copyright © 2021 scienceboard.net